ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF
申请人:Abbott GmbH & Co. KG
公开号:EP1392280A2
公开(公告)日:2004-03-03
EP1392280A4
申请人:——
公开号:EP1392280A4
公开(公告)日:2005-11-30
US6875765B2
申请人:——
公开号:US6875765B2
公开(公告)日:2005-04-05
[EN] ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF<br/>[FR] ETHERS ARYLSULFONAMIDE ET TECHNIQUES D'UTILISATION DE CES COMPOSES
申请人:ABBOTT GMBH & CO KG
公开号:WO2002089749A2
公开(公告)日:2002-11-14
Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family is also described. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.
Arylsulfonamide ethers, and methods of use thereof
申请人:——
公开号:US20030096826A1
公开(公告)日:2003-05-22
Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1&bgr; converting enzyme and other cysteine proteases in the ICE family is also decribed. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.